Protocol for an Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation Support for People With Severe Mental Illness

Introduction: Smoking is a major cause of disease burden and reduced quality of life for people with severe mental illness (SMI). It places significant resource pressure on health systems and financial stress on smokers with SMI (SSMI). Telephone-based smoking cessation interventions have been shown...

Full description

Bibliographic Details
Main Authors: Rohan Sweeney, Marj Moodie, Amanda L. Baker, Ron Borland, David Castle, Catherine Segan, Alyna Turner, John Attia, Peter J. Kelly, Lisa Brophy, Billie Bonevski, Jill M. Williams, Donita Baird, Sarah L. White, Kristen McCarter
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Psychiatry
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fpsyt.2019.00618/full
id doaj-e4f205f21cb44ad4acbf7dda971b9f0c
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Rohan Sweeney
Marj Moodie
Amanda L. Baker
Ron Borland
Ron Borland
David Castle
David Castle
Catherine Segan
Catherine Segan
Alyna Turner
Alyna Turner
John Attia
Peter J. Kelly
Lisa Brophy
Lisa Brophy
Billie Bonevski
Jill M. Williams
Donita Baird
Sarah L. White
Kristen McCarter
spellingShingle Rohan Sweeney
Marj Moodie
Amanda L. Baker
Ron Borland
Ron Borland
David Castle
David Castle
Catherine Segan
Catherine Segan
Alyna Turner
Alyna Turner
John Attia
Peter J. Kelly
Lisa Brophy
Lisa Brophy
Billie Bonevski
Jill M. Williams
Donita Baird
Sarah L. White
Kristen McCarter
Protocol for an Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation Support for People With Severe Mental Illness
Frontiers in Psychiatry
smoking
smoking cessation
mental illness
quitline
peer worker
economic evaluation
author_facet Rohan Sweeney
Marj Moodie
Amanda L. Baker
Ron Borland
Ron Borland
David Castle
David Castle
Catherine Segan
Catherine Segan
Alyna Turner
Alyna Turner
John Attia
Peter J. Kelly
Lisa Brophy
Lisa Brophy
Billie Bonevski
Jill M. Williams
Donita Baird
Sarah L. White
Kristen McCarter
author_sort Rohan Sweeney
title Protocol for an Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation Support for People With Severe Mental Illness
title_short Protocol for an Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation Support for People With Severe Mental Illness
title_full Protocol for an Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation Support for People With Severe Mental Illness
title_fullStr Protocol for an Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation Support for People With Severe Mental Illness
title_full_unstemmed Protocol for an Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation Support for People With Severe Mental Illness
title_sort protocol for an economic evaluation of the quitlink randomized controlled trial for accessible smoking cessation support for people with severe mental illness
publisher Frontiers Media S.A.
series Frontiers in Psychiatry
issn 1664-0640
publishDate 2019-09-01
description Introduction: Smoking is a major cause of disease burden and reduced quality of life for people with severe mental illness (SMI). It places significant resource pressure on health systems and financial stress on smokers with SMI (SSMI). Telephone-based smoking cessation interventions have been shown to be cost effective in general populations. However, evidence suggests that SSMI are less likely to be referred to quitlines, and little is known about the effectiveness and cost effectiveness of such interventions that specifically target SSMI. The Quitlink randomized controlled trial for accessible smoking cessation support for SSMI aims to bridge this gap. This paper describes the protocol for evaluating the cost effectiveness of Quitlink.Methods: Quitlink will be implemented in the Australian setting, utilizing the existing mental health peer workforce to link SSMI to a tailored quitline service. The effectiveness of Quitlink will be evaluated in a clustered randomized controlled trial. A cost-effectiveness evaluation will be conducted alongside the Quitlink clustered randomized controlled trial (RCT) with incremental cost-effectiveness ratios (ICERs) calculated for the cost (AUD) per successful quit and quality adjusted life year (QALY) gained at 8 months compared with usual care from both health care system and limited societal perspectives. Financial implications for study participants will also be investigated. A modeled cost-effectiveness analysis will also be conducted to estimate future costs and benefits associated with any treatment effect observed during the trial. Results will be extrapolated to estimate the cost effectiveness of rolling out Quitlink nationally. Sensitivity analyses will be undertaken to assess the impact on results from plausible variations in all modeled variables.Discussion: SSMI require additional support to quit. Quitlink utilizes existing peer worker and quitline workforces and tailors quitline support specifically to provide that increased cessation support. Given Quitlink engages these existing skilled workforces, it is hypothesized that, if found to be effective, it will also be found to be both cost effective and scalable. This protocol describes the economic evaluation of Quitlink that will assess these hypotheses.Ethics and dissemination: Full ethics clearances have been received for the methods described below from the University of Newcastle (Australia) Human Research Ethics Committee (H-2018-0192) and St Vincent’s Hospital, Melbourne (HREC/18/SVHM/154). The trial has been registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12619000244101). Participant consent is sought both to participate in the study and to have the study data linked to routine health administrative data on publicly subsidized health service and pharmaceutical use, specifically the Medicare Benefits and Pharmaceutical Benefits Schemes (MBS/PBS). Trial findings (including economic evaluation) will be published in peer reviewed journals and presented at international conferences. Collected data and analyses will be made available in accordance with journal policies and study ethics approvals. Results will be presented to relevant government authorities with an interest in cost effectiveness of these types of interventions.
topic smoking
smoking cessation
mental illness
quitline
peer worker
economic evaluation
url https://www.frontiersin.org/article/10.3389/fpsyt.2019.00618/full
work_keys_str_mv AT rohansweeney protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT marjmoodie protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT amandalbaker protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT ronborland protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT ronborland protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT davidcastle protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT davidcastle protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT catherinesegan protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT catherinesegan protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT alynaturner protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT alynaturner protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT johnattia protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT peterjkelly protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT lisabrophy protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT lisabrophy protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT billiebonevski protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT jillmwilliams protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT donitabaird protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT sarahlwhite protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
AT kristenmccarter protocolforaneconomicevaluationofthequitlinkrandomizedcontrolledtrialforaccessiblesmokingcessationsupportforpeoplewithseverementalillness
_version_ 1724871185097818112
spelling doaj-e4f205f21cb44ad4acbf7dda971b9f0c2020-11-25T02:20:27ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402019-09-011010.3389/fpsyt.2019.00618422210Protocol for an Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation Support for People With Severe Mental IllnessRohan Sweeney0Marj Moodie1Amanda L. Baker2Ron Borland3Ron Borland4David Castle5David Castle6Catherine Segan7Catherine Segan8Alyna Turner9Alyna Turner10John Attia11Peter J. Kelly12Lisa Brophy13Lisa Brophy14Billie Bonevski15Jill M. Williams16Donita Baird17Sarah L. White18Kristen McCarter19Centre for Health Economics, Monash Business School, Monash University, Melbourne, VIC, AustraliaDeakin Health Economics, Centre for Population Health Research, Deakin University, Geelong, VIC, AustraliaFaculty of Health and Medicine, University of Newcastle, Newcastle, NSW, AustraliaThe Cancer Council Victoria, Melbourne, VIC, AustraliaSchool of Psychological Sciences, University of Melbourne, Melbourne, VIC, AustralianDepartment of Psychiatry, University of Melbourne, Melbourne, VIC, AustraliaDepartment of Psychiatry, St Vincent’s Hospital Melbourne, Fitzroy, VIC, AustraliaThe Cancer Council Victoria, Melbourne, VIC, AustraliaMelbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, AustraliaIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia0Barwon Health, Geelong, VIC, AustraliaFaculty of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia1Illawarra Institute for Mental Health, School of Psychology, University of Wollongong, Wollongong, NSW, AustraliaMelbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia2Mind Australia, Melbourne, VIC, AustraliaFaculty of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia3Division of Addiction Psychiatry, Rutgers Robert Wood Johnson Medical School and Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United StatesFaculty of Health and Medicine, University of Newcastle, Newcastle, NSW, AustraliaThe Cancer Council Victoria, Melbourne, VIC, AustraliaFaculty of Health and Medicine, University of Newcastle, Newcastle, NSW, AustraliaIntroduction: Smoking is a major cause of disease burden and reduced quality of life for people with severe mental illness (SMI). It places significant resource pressure on health systems and financial stress on smokers with SMI (SSMI). Telephone-based smoking cessation interventions have been shown to be cost effective in general populations. However, evidence suggests that SSMI are less likely to be referred to quitlines, and little is known about the effectiveness and cost effectiveness of such interventions that specifically target SSMI. The Quitlink randomized controlled trial for accessible smoking cessation support for SSMI aims to bridge this gap. This paper describes the protocol for evaluating the cost effectiveness of Quitlink.Methods: Quitlink will be implemented in the Australian setting, utilizing the existing mental health peer workforce to link SSMI to a tailored quitline service. The effectiveness of Quitlink will be evaluated in a clustered randomized controlled trial. A cost-effectiveness evaluation will be conducted alongside the Quitlink clustered randomized controlled trial (RCT) with incremental cost-effectiveness ratios (ICERs) calculated for the cost (AUD) per successful quit and quality adjusted life year (QALY) gained at 8 months compared with usual care from both health care system and limited societal perspectives. Financial implications for study participants will also be investigated. A modeled cost-effectiveness analysis will also be conducted to estimate future costs and benefits associated with any treatment effect observed during the trial. Results will be extrapolated to estimate the cost effectiveness of rolling out Quitlink nationally. Sensitivity analyses will be undertaken to assess the impact on results from plausible variations in all modeled variables.Discussion: SSMI require additional support to quit. Quitlink utilizes existing peer worker and quitline workforces and tailors quitline support specifically to provide that increased cessation support. Given Quitlink engages these existing skilled workforces, it is hypothesized that, if found to be effective, it will also be found to be both cost effective and scalable. This protocol describes the economic evaluation of Quitlink that will assess these hypotheses.Ethics and dissemination: Full ethics clearances have been received for the methods described below from the University of Newcastle (Australia) Human Research Ethics Committee (H-2018-0192) and St Vincent’s Hospital, Melbourne (HREC/18/SVHM/154). The trial has been registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12619000244101). Participant consent is sought both to participate in the study and to have the study data linked to routine health administrative data on publicly subsidized health service and pharmaceutical use, specifically the Medicare Benefits and Pharmaceutical Benefits Schemes (MBS/PBS). Trial findings (including economic evaluation) will be published in peer reviewed journals and presented at international conferences. Collected data and analyses will be made available in accordance with journal policies and study ethics approvals. Results will be presented to relevant government authorities with an interest in cost effectiveness of these types of interventions.https://www.frontiersin.org/article/10.3389/fpsyt.2019.00618/fullsmokingsmoking cessationmental illnessquitlinepeer workereconomic evaluation